Trials / Completed
CompletedNCT04575259
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Anavex Life Sciences Corp. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
Detailed description
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANAVEX2-73 | Oral capsules |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2022-05-31
- Completion
- 2022-06-30
- First posted
- 2020-10-05
- Last updated
- 2022-08-01
Locations
10 sites across 2 countries: Australia, Spain
Source: ClinicalTrials.gov record NCT04575259. Inclusion in this directory is not an endorsement.